



## **Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference**

**SAN DIEGO, March 27, 2019** —Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its *Pf*enex Expression Technology® to improve protein therapies for unmet patient needs, announced today that Eef Schimmelpennink, Chief Executive Officer, and Susan Knudson, Chief Financial Officer, will be participating at the William Blair Late-Stage Therapeutics Conference, taking place April 4<sup>th</sup> at Omni Berkshire Place in New York City.

### **About Pfenex Inc.**

We are a clinical-stage development and licensing biotechnology company focused on leveraging our *Pf*enex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented *Pf*enex Expression Technology platform, we have created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company also uses its Pfenex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccines. Our lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and our novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, we are developing hematology/oncology products, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology, in collaboration with Jazz Pharmaceuticals.

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (<http://www.pfenex.com/>), our investor relations website (<http://pfenex.investorroom.com/>), press releases, SEC filings, public conference calls, corporate Twitter account (<https://twitter.com/pfenex>), Facebook page (<https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/>), and LinkedIn page (<https://www.linkedin.com/company/pfenex-inc>) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

### **Company Contact:**

Susan A. Knudson  
Chief Financial Officer  
(858) 352-4324  
[sknudson@pfenex.com](mailto:sknudson@pfenex.com)